Background and Purpose-The adipocytokines adiponectin and leptin have been suggested as risk factors for cardiovascular disease, including stroke, acting through atherosclerosis. However, studies have provided conflicting results in underpowered cohorts with some suggesting that the leptin:adiponectin ratio is a better predictor of risk. We examined these associations with carotid intima-media thickness (IMT), a marker of early atherosclerosis and arterial remodeling and an independent predictor of stroke. We also examined association between genetic variants in the leptin and adiponectin genes and IMT. Methods-Adiponectin and leptin levels were determined in 990 individuals from the community Carotid Atherosclerosis Progression Study. Five variants in the gene encoding adiponectin and 7 in the gene encoding leptin were genotyped and their effects on circulating levels assessed. Both were then correlated with IMT. Results-Adiponectin levels negatively correlated with IMT (Ϫ0.079, Pϭ0.013). There was no correlation between leptin levels or leptin:adiponectin ratio and IMT. Two variants in the ADIPOQ gene encoding adiponectin were associated with altered adiponectin levels, 1 of which (rs266729) was associated with IMT. There was also an interaction with body mass index (Pϭ0.019) with the association being present in obese subjects (Pϭ0.02). Conclusions-Our results support a causal role for adiponectin in early carotid IMT and suggest it may act through interaction with obesity. In contrast, we found no evidence of a role for leptin and no evidence that leptin:adiponectin ratio is a better predictor of risk that adiponectin levels alone. (Stroke. 2011;42:1510-1514.)
I
ncreasing evidence suggests adipocytokines increase atherosclerosis and therefore risk of cardiovascular disease, including stroke. Two of the most abundant adipocytokines, adiponectin and leptin, have effects on inflammatory responses in the body. Serum adiponectin levels have been associated with cardiovascular events and/or mortality in cardiovascular disease, including peripheral artery disease 1, 2 and chronic kidney disease. 3 Leptin has been associated with endothelial dysfunction and cardiovascular disease 4 and suggested as a link among obesity, the metabolic syndrome, and cardiovascular disease. 5 In obese subjects, leptin levels are elevated, whereas adiponectin levels are decreased. There remains uncertainty, however, about the strength of associations between cardiovascular disease and individual adipocytokines with some studies suggesting associations are mediated through diabetes 6 and that the ratio between adiponectin and leptin may be a better biomarker of disease risk. 7 The relationship between novel risk factors and carotid atherosclerosis can be studied by measurement of carotid intima-media thickness (IMT). This is measured simply and noninvasively using ultrasound. It is increased in subjects with cardiovascular risk factors and an independent predictor of future stroke and myocardial infarction. 8 It provides information on whether risk factors are associated with the early stages of atherosclerosis and remodeling.
Although associations between adiponectin and leptin levels on carotid IMT have been reported, albeit with conflicting results, 9 -11 associations between the leptin:adiponectin (L:A) ratio and carotid IMT have been less well documented. Plasma L:A ratio has been correlated with pulse wave velocity in obese diabetic patients 12 with IMT in elderly diabetic Japanese patients 7 and with carotid IMT in a healthy males. 13 However, a subsequent investigation in healthy elderly females showed no association. 14 Further studies are warranted, particularly because all of these studies were on very small cohorts.
Leptin and adiponectin levels are also influenced by the presence of genetic variation in their coding genes. Polymorphisms in ADIPOQ, which codes for adiponectin, have been associated with diabetes and the metabolic syndrome 15, 16 and with adiponectin levels in multiple populations. [17] [18] [19] The involvement of specific haplotypes, or compound heterozygotes, has been proposed as a mechanism for variation in adiponectin levels. 19 In addition, genetic variation in the ADIPOQ promoter has been associated with IMT independent of adiponectin levels. 20 This finding concurs with the reported role of adiponectin levels in high-risk or disease populations. 21, 22 Genetic variation in leptin has been well documented with variants in the gene encoding leptin shown to alter circulating levels. 23 Leptin levels have been associated with both hemorrhagic stroke 24 and cerebrovascular disease in men 25, 26 and an increased IMT. 27 We therefore investigated the relationship among adiponectin, leptin, and the L:A ratio with IMT in a large population cohort, the Carotid Atherosclerosis Progression Study (CAPS). We also genotyped functional variants in the adiponectin and leptin genes and determined whether these were associated with IMT. Low adiponectin levels in the presence of obesity are considered to be a major determinant of insulin resistance, itself an intermediate risk factor for diabetes and cardiovascular disease. 11 To examine whether a causal pathway exists from low adiponectin as a consequence of obesity to cardiovascular risk through insulin resistance, we also examined interactions between body mass index (BMI) and glycosylated hemoglobin and genetic variation in ADIPOQ.
Materials and Methods

Subjects
Details of the CAPS cohort have been published. 28 In brief, members of a German primary healthcare service population (nϭ32 708) were invited to participate. Within a predefined time limit, 6962 (21.3%) agreed. The first 990 individuals in whom carotid IMT measurements were performed, and in whom there was sufficient DNA, were included in this study. Informed written consent was obtained from all participants, and the study protocol was approved by the local ethical committee.
Vascular risk factors were assessed using a standardized computer-assisted interview performed by a physician experienced in vascular medicine. Common carotid IMT was measured using a 7.5-to 10.0-MHz linear array transducer (P700SE; Phillips Medical System) with a standard protocol as previously published. 28 Images were digitally captured during the systole of a single heartbeat and mean IMT determined using semiautomated software with high inter-and intraobserver reproducibility. 28 The mean of left and right IMT was used in all analyses.
Laboratory Methods
Five polymorphisms in the ADIPOQ gene, and 7 in the gene encoding leptin, were selected on the basis of previous publications implicating them as functional or associated with BMI and other cardiovascular risk factors. 23,29 -32 They were labeled as adiop1-5 and leptin1-7. rs identifiers for each of the variants are shown in the Supplemental Tables (http: //stroke.ahajournals.org). DNA was extracted from whole blood using Nucleon Kits (Tepnel Life Sciences). Genotyping was performed using a fluorescent detection KASPAR protocol at a commercial genotyping facility (www.kbioscience.co.uk).
Circulating plasma adiponectin and leptin levels were measured using enzyme-linked immunosorbent assay kits from RϩD systems (Abingdon, UK). These have lower detection limits of 0.2 ng/mL and 8 pg/mL for adiponectin and leptin, respectively. Mean human adiponectin plasma levels are 6641 ng/mL, and mean human leptin plasma levels are 4760 pg/mL (men) and 20 676 pg/mL (women). Adiponectin levels detected by the kit include all forms of adiponectin protein, including monomers, low-molecular-weight hexamers, and high-molecular-weight multimers to give a "total" adiponectin reading. Levels of both cytokines were determined in all 990 samples using an EMAX plate reader (Molecular Devices, Wokingham, UK) with a detection filter of 450 nm wavelength.
Statistical Analysis
All statistics were performed in SPSS Version 15. Adiponectin levels were square root transformed to obtain a normal distribution. No transformation of leptin levels was required. Bonferroni correction was performed to account for the number of variants examined and the number of models. Correction for age, gender, BMI, glycosylated hemoglobin, hypertension, smoking (pack-years), and total cholesterol was performed. Interaction analysis was performed by adding a gene-environment term in the linear regression model. If the term was significant, then the population was split by the environmental interaction (in this instance, BMI Ͼ30 kg/m
2 ) and each group tested under the same linear regression model, that is, with inclusion of all previous significant risk factors (minus the interaction term) and the genotype assessed for significance. To prevent overfitting and multiple testing, only BMI was tested as an interaction term because our prior hypothesis was that variants in the genes tested may exert an effect through obesity-related mechanisms. Associations between adiponectin level, leptin level, or L:A ratio and IMT were assessed using 2-sided Pearson correlation tests.
Assuming a probability value of 0.001 and power of 80%, it would require 845 cases to detect an effect of 2% variance in IMT. We have examined 12 variants in this study giving a Bonferroni-corrected probability value of Pϭ0.004. With 1000 cases, we were therefore powered to detect Ͻ2% variation in IMT within the CAPS population. 33 Genetic power calculations were performed using the genetic power calculator QUANTO available from http://hydra.usc.edu/gxe/.
Results
Adipocytokine Levels and Carotid IMT
Population demographics are shown in Table 1 . There was a significant negative correlation between adiponectin levels and carotid IMT (correlation coefficient Ϫ0.079; Pϭ0.013), which remained after correcting for age and gender (Ϫ0.113; Pϭ0.001) and for age, gender, and BMI (Ϫ0.082; Pϭ0.016).
In contrast, there was no correlation between leptin and IMT (0.013; Pϭ0.674) or between L:A ratio and IMT (0.037; Pϭ0.250). Given the difference between males and females in circulating leptin levels, we also performed an analysis in genders individually, but there was no association between L:A ratio and IMT in either group (data not shown). Correlations among traditional cardiovascular risk factors, adipocytokines, and IMT are shown in Table 2 . This table also shows stratification by gender for these risk factors.
Internal carotid artery and bifurcation IMT were also measured in the CAPS populations in all 990 subjects; similar associations between these measures and adiponectin levels were found. (internal carotid artery rϭϪ0.078, Pϭ0.014; bifurcation correlation rϭϪ0.082, Pϭ0.010). No association was identified between these 2 measures and either leptin levels or L:A ratio (data not shown), consistent with the data for common carotid artery IMT.
Genetic Polymorphisms and Adipocytokine Levels
All genetic variants were in Hardy-Weinberg equilibrium. Associations between these variants and adipocytokine levels are shown in Supplemental Table 1 . There was no association identified for any variant in leptin and circulating plasma leptin level under any model.
In contrast, associations were detected with ADIPOQ variants under a fully adjusted model. Single nucleotide polymorphisms adipo2 (rs1501299; Pϭ0.002), adipo3 (rs17300539; PϽ0.001), and adipo4 (rs266729; Pϭ0.002) had nominally significant effects on adiponectin levels after correction for age, gender, BMI, and glycosylated hemoglobin. Adipo2 and adipo3 were associated with higher adiponectin levels and adipo4 with lower levels (Supplemental Table 2 ). After correction for multiple testing, only variants adipo3 and adipo4 remained associated with adiponectin levels. Variant adipo3 would thus be hypothesized to be a protective factor for increased carotid IMT and adipo4 a risk factor for increased IMT if adiponectin levels have a direct effect on IMT. Only a dominant model was sufficiently powered for analysis, although we have included all models in tables for completeness.
Genetic Polymorphisms and Carotid IMT
Examination of genetic variants in the gene encoding leptin revealed no association with IMT (data not shown). Examining associations between genetic variants in adiponectin and IMT revealed only adipo4 (rs266729) showed a significant association with carotid IMT. This association weakened but remained significant when correcting for age and gender.
There was a significant (Pϭ0.019) interaction between BMI and adipo4 with IMT (Supplemental Table 3 ). To explore this further, the cohort was divided into obese (BMI Ն30 kg/m 2 ) and nonobese subjects (BMI Ͻ30 kg/m 2 ). In obese subjects, there was a significant association between adipo4 and IMT (dominant model, Pϭ0.02), but there was no association in nonobese subjects (Pϭ0.715). As expected, adiponectin levels were also significantly lower in obese subjects regardless of genotype at adipo4 (Pϭ0.001).
Discussion
In a large community-based population, we confirmed an inverse relationship between adiponectin levels and carotid IMT. If this represents a causal relationship, one would expect an association between genetic variants resulting in altered adiponectin levels with increased IMT. We identified 2 variants that independently affected circulating adiponectin levels, adipo3 (rs17300539) and adipo4 (rs266729). One of these variants (adipo4) was weakly associated with carotid IMT, which increased in the presence of the variant in obese subjects, whereas there was no effect in nonobese subjects. This variant was associated with low adiponectin levels and therefore would be expected to be a risk factor for increased atherosclerosis. This association persisted after controlling for glycosylated hemoglobin as a measure of glucose intolerance, suggesting that genetic variants in the ADIPOQ gene may act directly through altering adiponectin levels to increase cardiovascular disease risk rather than through inducing glucose intolerance. In contrast to the associations with adiponectin, we found no association between leptin levels and IMT. Consistent with this, we found no association between leptin gene variants and IMT. We found a lack of association between genetic variants and leptin levels, which does not agree with previously reported studies, although 1 explanation for this could be that we have studied a healthy population, whereas previously reported significant associations were in higher risk and obese subjects. 23 It has been suggested L:A ratio may be a better marker of risk, and recent small studies have found associations with IMT. 7, 13 In this much larger cohort, we found no association between L:A ratio and IMT. It has been suggested this association may be present only in males, but we were unable to confirm this.
A number of studies have previously demonstrated an association between adiponectin and cardiovascular disease, including IMT. Such associations should be treated cautiously because any change in levels may be secondary to disease. Consequently, studying functional genetic variants associated with altered levels of circulating markers contributes useful information because genetic risks represent lifelong exposure to risk. Therefore, the association identified between ADIPOQ and IMT supports a causal relationship between adiponectin and IMT. The strong interaction with BMI emphasizes the importance of gene-environment interactions in the pathogenesis of atherosclerosis. The association with IMT was present only in individuals with elevated BMI. This is consistent with previous data showing that proinflammatory genes predispose to increasing IMT primarily through an interaction with proinflammatory environmental risk factors, including smoking and chronic infection. 33 Our protocol specified analysis was in common carotid IMT. However, we also examined associations with internal carotid and bifurcation IMT. Similar associations were found with adipocytokine levels, although we did not detect associations between IMT at these locations and ADIPOQ or an interaction with BMI. This may partly reflect the increased measurement error at these sites but emphasizes that further studies are required to confirm our findings relating ADIPOQ to common carotid IMT.
This study has some limitations. Without longitudinal IMT measurements, it is difficult to ascribe causality to the genetic variants identified. Although follow-up is available in CAPS, this was only available for a limited number of these 1000 individuals and therefore we did not have the power to reliably look for associations with progression. In addition, in CAPS, we have previously shown that risk factors correlate much more strongly with cross-sectional data than with longitudinal progression, reflecting the relatively small amount of progression over 3 years and measurement error, both reducing power to detect associations 34 The CAPS population is also a relatively young population with a low incidence of plaque and therefore we were not able to perform analyses with the presence of established plaque, which is a better measure of established atherosclerosis; further studies in cohorts with established plaque would be useful.
In conclusion, our results support a causal role of adiponectin in early atherosclerosis and vessel remodeling and suggest it may act through an interaction with obesity. We found no evidence for leptin in risk and no evidence that the ratio of leptin and adiponectin levels is a better predictor of risk that adiponectin levels alone. 
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From 和日本的老年糖尿病患者的 IMT [7] 以及和健康男性 的颈动脉 IMT [13] 都是相关的。然而，随后的与老年 女性的调查研究却没有发现相关性 [14] 。进一步的研 究被批准，主要是因为所有的这些研究都是基于小 样本的。 瘦素和脂联素水平也受其编码基因的遗传变异 的影响。ADIPOQ 基因是脂联素的编码基因，它的 多态性曾被认为与糖尿病和代谢综合征 [15, 16] 有关， 并且与正态群体的脂联素水平有关 [17] [18] [19] 。特异的单 体型的混合，或者杂合子的结合，已被提议是脂联 素水平变异的基础 [19] 。另外，独立于脂联素水平， ADIPOQ 启动子的遗传变异被认为和 IMT 有关 [20] 。 这项发现和被报道过的高风险或患病人群的脂联素 的作用是一致的 [21, 22] 。 瘦素的基因变异和编码瘦素基因的多样性在循 环水平的变化曾一起被探讨过 [23] 。瘦素水平不仅和 出血性卒中 [24] 有关，还与男性脑血管病 [25, 26] 以及 
